Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Tardive Dyskinesia Market Outlook

The tardive dyskinesia market size is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, driven by the rising incidence of mood disorders leading to heightened application of antipsychotic medications in patients across the major markets.

Tardive Dyskinesia Market Overview

Tardive dyskinesia is a medical condition characterized by involuntary movements in the body as a side effect of antipsychotic medications, neuroleptic drugs or major tranquilizers commonly used to treat mental problems. The prevalence rate is at least 20 % in all the patients who have encountered first generation neuroleptics as some form of treatment. Middle-aged to senior women are more susceptible to develop the condition as compared to men. Post-menopausal women have a 30% higher incidence rate. It can be broadly categorized into orofacial dyskinesia which leads to uncontrollable movements in the face and dyskinesia of the limbs, affecting arms, legs, toes, and fingers. The most frequently occurring symptoms involve spontaneous movements of mouth and tongue.

Increasing Burden of Mood Disorders

The tardive dyskinesia market demand is driven by the growing prevalence of mental disorders such as schizophrenia, bipolar disorder, major depressive disorder, and schizoaffective disorder. Major depressive disorder is a common psychiatric disorder with an average lifetime prevalence rate of 12% . Globally 46 million  people around the world are living with bipolar disorder, out of which 2.8% constitute the United States population. Schizophrenia affects approximately 24 million people  worldwide. Therefore, the rising incidence of such conditions has led to increased application of antipsychotic medications, impacting the tardive dyskinesia market significantly.

Rising FDA Approvals for New Drug Formulations to Bolster the Tardive Dyskinesia Market Growth

In September 2023, Neurocrine Biosciences’  valbenazine oral granules called Ingrezza got accepted by the FDA for a New Drug Application (NDA) review. A selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Valbenazine, showed positive results in the analysis of the three studies (KINECT™ 3, KINECT™ 4, and J-KINECT™) wherein the drug administration resulted in sustained and substantial disease improvement in patients. The surge in clinical trials and expediated drug development with the help of the latest technologies is a key driver leading to enhanced tardive dyskinesia market share.

Surge in Research Activities for Improved Treatment Alternatives

The market growth is fueled by the expediated drug development and clinical trials to maintain efficacy and offer quality solutions for patients. Clonazepam , a benzodiazepine with indirect GABA agonist activity, Amantadine, a blocker of N-methyl-D-aspartate glutamate receptors and Tetrabenazine, a selective VMAT2 inhibitor are some key drugs under consideration to be used as an option. Gingko biloba, which acts as an antioxidant, also demonstrated potential efficacy in decreasing symptoms by using brain-derived neurotrophic factor signaling as a plan of action.

Tardive Dyskinesia Market Segmentation

Market Breakup by Type

  • Bradykinesias
  • Hyperkinesias

Market Breakup by Drug Class

  • Dopamine-Depleting Medications
  • VMAT2 inhibitors
  • GABA Receptor agonist medications
  • Anticholinergic Medications

Market Breakup by End User

  • Hospital
  • Clinics

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

Tardive Dyskinesia Market Regional Analysis

Owing to high incidence of mental disorders, the United States has witnessed ample tardive dyskinesia market growth in the historical period. The presence of vital pharmaceutical companies and rising mergers and collaborations amongst them to boost their product portfolio played a critical role in the substantial market share.

With a robust medical and research infrastructure, Europe is also a key market for tardive dyskinesia. Along with a well-structured regulatory framework, the government plays a pivotal role in setting up numerous campaigns to educate the public about mental health disorders and the underlying side effects it may offer.

The Asia Pacific region is expected to witness a growth in the tardive dyskinesia market share, owing to the growth in drug launches. In July 2023, Japan based Mitsubishi Tanabe Pharma Corporation launched REMLEAS  as the new tardive dyskinesia treatment drug. The drug has received marketing approval across 3 major ASEAN countries including Thailand, Indonesia, and Singapore. REMLEAS is a vesicular monoamine transporter type 2 inhibitor which reduces dopamine intake to treat the symptoms in patients.

Tardive Dyskinesia Market: Competitor Landscape

In February 2023, Teva Pharmaceuticals  received FDA approval for AUSTEDOXR (deutetrabenazine), a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). It is an additional formulation to the currently marketed twice daily formula and is made available in multiple tablet strengths like 6 mg, 12 mg, and 24 mg. It can be administered with or without food as well. The new formula may lead to a decreased pill count in the patients, indicating the rising emphasis on offering convenience to the patients. Innovation and increased research activities in drug development is a major trend adopted by prominent companies across major markets.

The key features of the tardive dyskinesia market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Teva Pharmaceutical Industries
  • Medicure Inc
  • Mylan N.V
  • Bionpharma
  • Hetero
  • Johnson & Johnson Services, Inc.
  • Bausch Health
  • Sanofi
  • GlaxoSmithKline Plc.
  • Lupin Pharmaceuticals Inc
  • Amgen Inc
  • Novartis AG
  • Lilly
  • Lannett Co Inc
  • Neurocrine Biosciences, Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Drug Class
  • End User
  • Region
Breakup by Type
  • Bradykinesias
  • Hyperkinesias
Breakup by Drug Class
  • Dopamine-Depleting Medications
  • VMAT2 inhibitors
  • GABA Receptor Agonist Medications
  • Anticholinergic Medications
Breakup by End User
  • Hospital
  • Clinics
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Teva Pharmaceutical Industries
  • Medicure Inc
  • Mylan N.V
  • Bionpharma
  • Hetero
  • Johnson & Johnson Services, Inc.
  • Bausch Health
  • Sanofi
  • GlaxoSmithKline Plc.
  • Lupin Pharmaceuticals Inc
  • Amgen Inc
  • Novartis AG
  • Lilly
  • Lannett Co Inc
  • Neurocrine Biosciences, Inc

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 3.2% during the forecast period of 2024-2032, driven by the rising incidence of mood disorders.

The market demand is driven increasing prevalence for personalised medicines that addresses the specific symptoms of a patient and offer relevant interventions as per the requirement. The increasing research and development in drug discovery is a major driver.

The increasing research and development in drug discovery and rising FDA approvals is a major market trend. In September 2023, Ingrezza, developed by Neurocrine Biosciences received FDA approval to be treat tardive dyskinesia in patients. In addition, numerous drugs such as Clonazepam, Amantadine and Tetrabenazine are under clinical trials and have shown promising results.

Based on diagnostic types, the market is divided into dopamine-depleting medications, VMAT2 inhibitors, GABA receptor agonist medications and anticholinergic medications.

The types can be categorised into bradykinesias and hyperkinesias.

Major end users in the market include hospitals and clinics.

The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.

Key players involved in the market are Teva Pharmaceutical Industries, Medicure Inc., Mylan N.V, Bionpharma, Hetero, Johnson & Johnson Services, Inc., Bausch Health, Sanofi, GlaxoSmithKline Plc., Lupin Pharmaceuticals Inc., Amgen Inc., Novartis AG, Lilly, Lannett Co Inc., and Neurocrine Biosciences, Inc.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124